These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 28199980

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.
    Kakavand H, Wilmott JS, Menzies AM, Vilain R, Haydu LE, Yearley JH, Thompson JF, Kefford RF, Hersey P, Long GV, Scolyer RA.
    Clin Cancer Res; 2015 Jul 15; 21(14):3140-8. PubMed ID: 25609064
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bone marrow mesenchymal stromal cells attenuate liver allograft rejection may via upregulation PD-L1 expression through downregulation of miR-17-5p.
    Chen Q, Zhou R, Zhang Y, Zhu S, Xiao C, Gong J, Li K, Tang H, Sun C, Zhang J.
    Transpl Immunol; 2018 Dec 15; 51():21-29. PubMed ID: 30092337
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dual MAPK Inhibition Triggers Pro-inflammatory Signals and Sensitizes BRAF V600E Glioma to T Cell-Mediated Checkpoint Therapy.
    Xing YL, Grossauer S, Park JW, Nasajpour E, Bui B, Morales D, Panovska D, Nirschl JJ, Feng ZP, Wei R, Koeck K, Thomason W, Xiu J, Harter PN, Filipski K, Mahaney K, Ji X, Mulcahy Levy JM, Grant GA, Prolo LM, Walsh KM, Lim M, Hambardzumyan D, Petritsch CK.
    bioRxiv; 2024 Oct 07. PubMed ID: 39416185
    [Abstract] [Full Text] [Related]

  • 10. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
    Goldinger SM, Zimmer L, Schulz C, Ugurel S, Hoeller C, Kaehler KC, Schadendorf D, Hassel JC, Becker J, Hauschild A, Dummer R, Dermatology Cooperative Oncology Group (DeCOG).
    Eur J Cancer; 2014 Jan 07; 50(2):406-10. PubMed ID: 24183461
    [Abstract] [Full Text] [Related]

  • 11. miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.
    Liu S, Tetzlaff MT, Wang T, Yang R, Xie L, Zhang G, Krepler C, Xiao M, Beqiri M, Xu W, Karakousis G, Schuchter L, Amaravadi RK, Xu W, Wei Z, Herlyn M, Yao Y, Zhang L, Wang Y, Zhang L, Xu X.
    Pigment Cell Melanoma Res; 2015 Jul 07; 28(4):431-41. PubMed ID: 25903073
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Nrf2 as a Therapeutic Target in the Resistance to Targeted Therapies in Melanoma.
    Cucci MA, Grattarola M, Monge C, Roetto A, Barrera G, Caputo E, Dianzani C, Pizzimenti S.
    Antioxidants (Basel); 2023 Jun 20; 12(6):. PubMed ID: 37372043
    [Abstract] [Full Text] [Related]

  • 15. Safety and Tolerability of BRAF Inhibitor and BRAF Inhibitor-Based Combination Therapy in Chinese Patients With Advanced Melanoma: A Real World Study.
    Liu X, Li JJ, Ding Y, Li DD, Wen XZ, Weng DS, Wang JH, Jiang H, Zhang XS.
    Front Oncol; 2021 Jun 20; 11():582676. PubMed ID: 33868987
    [Abstract] [Full Text] [Related]

  • 16. RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.
    Chen X, Chen S, Xiu YL, Sun KX, Zong ZH, Zhao Y.
    Mol Cancer; 2015 Feb 04; 14(1):31. PubMed ID: 25649143
    [Abstract] [Full Text] [Related]

  • 17. miREIA - an immunoassay method in assessment of microRNA levels in tumor tissue-pilot study. The impact of miR-93-5p, miR-142-5p and IFNγ on PD-L1 level in colorectal cancer.
    Dawidowicz M, Kula A, Mielcarska S, Kiczmer P, Gołąbek K, Ostrowska Z, Waniczek D, Świętochowska E.
    Acta Biochim Pol; 2021 Apr 07; 68(2):247-254. PubMed ID: 33826281
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care.
    Louveau B, Jouenne F, Reger de Moura C, Sadoux A, Baroudjian B, Delyon J, Herms F, De Masson A, Da Meda L, Battistella M, Dumaz N, Lebbe C, Mourah S.
    Cancers (Basel); 2019 Aug 18; 11(8):. PubMed ID: 31426590
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.